97 related articles for article (PubMed ID: 27258564)
1. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
[TBL] [Abstract][Full Text] [Related]
2. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
3. ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples samples.
Cai J; Yang P; Zhang C; Zhang W; Liu Y; Bao Z; Liu X; Du W; Wang H; Jiang T; Jiang C
Oncotarget; 2014 May; 5(9):2551-61. PubMed ID: 24810474
[TBL] [Abstract][Full Text] [Related]
4. Chaperonin-containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients.
Hu Y; Fu P; Zhao H; Zhang F; Jiang X; Zhao W; Lv P
J Clin Lab Anal; 2021 Sep; 35(9):e23917. PubMed ID: 34312925
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutation detection by droplet digital PCR in glioma.
Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
[TBL] [Abstract][Full Text] [Related]
6. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
[TBL] [Abstract][Full Text] [Related]
7. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.
Chitikova Z; Pusztaszeri M; Makhlouf AM; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
Oncotarget; 2015 May; 6(13):10978-93. PubMed ID: 25868389
[TBL] [Abstract][Full Text] [Related]
8. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
9. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
[TBL] [Abstract][Full Text] [Related]
11. Hsp27 and its expression pattern in diffusely infiltrating astrocytomas.
Mäkelä KS; Haapasalo JA; Ilvesaro JM; Parkkila S; Paavonen T; Haapasalo HK
Histol Histopathol; 2014 Sep; 29(9):1161-8. PubMed ID: 24599602
[TBL] [Abstract][Full Text] [Related]
12. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
13. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
14. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
15. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
16. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
17. Identification of two core genes in glioblastomas with different isocitrate dehydrogenase mutation status.
Guo Y; Wang X; Ning W; Zhang H; Yu C
Mol Biol Rep; 2020 Oct; 47(10):7477-7488. PubMed ID: 32915403
[TBL] [Abstract][Full Text] [Related]
18. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
[TBL] [Abstract][Full Text] [Related]
19. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
20. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
